Pharmacology Research & Perspectives · 2015 · 25 citations · 26 references
MedicineOncologyPharmacologyDna RepairDrug DiscoveryMolecular OncologyCancer EpigeneticsChromatinChromatin InteractionsLigand BindingTargeted Cancer TherapyBinding Site SpecificityCancer Cell Proliferation InhibitionDrug Target ValidationOn-target ValidationPotency ComparisonSelective Cancer TherapyTherapeutic Target Validation
Proliferating cell nuclear antigen (PCNA) plays an essential role in DNA replication and repair. Tumor cells express high levels of PCNA, identifying it as a potentially ideal target for cancer therapy. Previously, we identified nine compounds termed PCNA inhibitors (PCNA-Is) that bind directly to PCNA, stabilize PCNA trimer structure, reduce chromatin-associated PCNA, and selectively inhibit tumor cell growth. Of these compounds, PCNA-I1 was most potent. The purpose of this study is to further establish targeting of PCNA by PCNA-I1 and to identify PCNA-I1 analogs with superior potencies. We found that PCNA-I1 does not affect the level of chromatin-associated PCNA harboring point mutations at the predicted binding site of PCNA-I1. Forty-six PCNA-I1 analogs with structures of 1-hydrazonomethyl-2-hydroxy (scaffold A), 2-hydrazonomethyl-1-hydroxy (scaffold B), 2-hydrazonomethyl-3-hydroxy (scaffold C), and 4-pyridyl hydrazine (scaffold D) were analyzed for their effects on cell growth in four tumor cell lines and PCNA trimer stabilization. Compounds in scaffold group A and group B showed the highest trimer stabilization and the most potent cell growth inhibitory activities with a significant potency advantage observed in the Z isomers of scaffold A. The absence of trimer stabilization and growth inhibitory effects in compounds of scaffold group D confirms the essentiality of the hydroxynaphthyl substructure. Compounds structure-activity relationship (SAR)-6 and SAR-24 were analyzed for their effects on and found to reduce chromatin-associated PCNA in tumor cells. This study led to the identification of SAR-24, a compound with superior potencies and potentially improved solubility, which will be used for future development of PCNA-targeting cancer therapies.
26
Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA
Talluru S.R. Krishna, Xiang‐Peng Kong, Sonja L. Gary et al. · Cell · 1994 · 916 citations
Structure of the C-Terminal Region of p21WAF1/CIP1 Complexed with Human PCNA
Jacqueline M. Gulbis, Zvi Kelman, J Hurwitz et al. · Cell · 1996 · 810 citations · Full text
Dynamics of DNA Replication Factories in Living Cells
Heinrich Leonhardt, Hans-Peter Rahn, Peter Weinzierl et al. · The Journal of Cell Biology · 2000 · 591 citations · Full text